Alembic Pharmaceuticals announces USFDA Final Approval for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg.
Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg have an estimated market size of US$ 17 million for twelve months ending June 2020 ...
Oct 21